Anal human papillomavirus and its associations with abnormal anal cytology among men who have sex with men

Ping-Feng Wu1,2,3, Jen-Fan Hang2,4, Carol Strong5, Su-Jung Chen1,2, Li-Ya Lin2,4, Shu-Sheng Chen1, Chiung-Ru Lai2,4, Stephane Wen-Wei Ku1,6,7 & Mei-Hsuan Lee3,7*

Human papillomavirus (HPV) infection contributes to most anal cancers and premalignant intraepithelial lesions. This study investigated anal HPV infections and cytological abnormalities among men who have sex with men (MSM). Sociodemographic characteristics and sexual behaviors were collected by using a structured questionnaire. Anal cytological results were examined, and HPV genotyping was performed by the Linear Array HPV Genotyping test. Logistic regression was used to estimate risk factors and their associations with high-risk HPV infection and cytological abnormalities. Among 163 MSM, 101 were seropositive for human immunodeficiency virus (HIV) and 62 were seronegative for HIV. The overall prevalence of HPV was 66.2%. A total of 61.9% and 48.2% of participants had never acquired any of either the quadrivalent or nonavalent vaccine HPV types, respectively. Cytological findings showed 15.3% atypical squamous cells of undetermined significance, 16.6% low-grade squamous intraepithelial lesion, 4.9% atypical squamous cells that cannot exclude high-grade squamous intraepithelial lesion, and 17% high-grade squamous intraepithelial lesion. The number of high-risk HPV types was the predominant risk factor for abnormal anal cytology (OR 2.02, 95% CI 1.27–3.24). Infection with high-risk HPV was a significant predictor for cytological abnormality. MSM should be encouraged to obtain the HPV vaccine.

Human papillomavirus (HPV) is an important cause of sexually transmitted diseases worldwide and is associated with malignant transformations in the squamous epithelium of the anus1. A rising trend in the incidence of anal cancer has been shown in recent years, increasing from 0.8 per 100,000 person-years in 1975 to 1.8 per 100,000 person-years in 2014 in the United States2. The development of anal cancer or pre-cancerous lesions is associated with one's lifetime number of sexual partners, human immunodeficiency virus (HIV) infection, receptive anal intercourse and anal HPV infection, particularly infection with HPV16–3. Moreover, among individuals with anal cancer, nearly 90% of cases are attributable to HPV infection5. A recent meta-analysis also showed that the increased prevalence of HPV is associated with the severity of abnormal anal cytology7.

The incidence of anal cancer among patients with HIV infection is much higher than among the general population (51.4 versus 1.2 per 100,000 person-years)8. HIV infection may attenuate the host’s immune competence, which then worsens the control of anal HPV infections9–11. In addition, HIV seropositives have a decreased probability of clearing anal HPV infection and have prolonged anal HPV infections, compared to HIV seronegatives11. The persistent anal HPV infections have been particularly found in high-risk HPV types, which are the predominant risk factors for anal cancer9,10. Thus, HIV infection is considered one of the most important independent risk factors for high-risk anal HPV infection14–17.

1Division of Infectious Diseases, Department of Medicine, Taipei Veterans General Hospital, Taipei, 112, Taiwan. 2School of Medicine, National Yang-Ming University, Taipei, 112, Taiwan. 3Institute of Clinical Medicine, National Yang-Ming University, Taipei, 112, Taiwan. 4Department of Pathology and Laboratory Medicine, Taipei Veterans General Hospital, Taipei, 112, Taiwan. 5Department of Public Health, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, 701, Taiwan. 6Division of Infectious Diseases, Department of Medicine, Taipei City Hospital Renai Branch, Taipei, 106, Taiwan. 7These authors contributed equally: Stephane Wen-Wei Ku and Mei-Hsuan Lee. *Email: meihlee@ntu.edu.tw
Anal HPV infection is mainly transmitted through anal intercourse, which is usually considered as a major high-risk sexual behavior in men who have sex with men (MSM)\(^1\). A previous meta-analysis found that the prevalence of anal HPV infection and epithelial dysplasia among MSM greatly exceeded the prevalence in the cervix among women\(^3\). Moreover, among the HIV infected population, the prevalence of any anal HPV type was 96% among MSM, 90% among women and 59% among men who have sex with women, suggesting that the acquisition of anal HPV infection is dependent on sexual behaviors\(^19\). However, most of the previous studies were mainly confined to HIV seropositive MSM. Data comparing HPV prevalence among both HIV seropositive and seronegative MSM is limited.

Therefore, this study aimed to evaluate the associations of HPV infection with the risk of abnormal anal dysplasia among MSM. Moreover, the different types or numbers of HPV infections were estimated by stratifying by HIV seronegatives and seropositives.

## Results

There were 163 MSM enrolled in this study; 101 were HIV seropositive, and 62 were HIV seronegative. Table 1 shows the baseline characteristics of the study participants. The median age among HIV seropositives was 32 years (interquartile range, IQR, 28–38 years old) compared to 29 years (IQR, 26–34 years old) among HIV seronegatives (\(p = 0.004\)). HIV seropositives had a higher percentage of smokers than HIV seronegatives (25.7% versus 8.1%, \(p = 0.010\)). Among HIV seropositives, 78.2% had undetectable HIV RNA. In addition, the median CD4\(^+\) cell count was 551 cells/µl (IQR, 430–730 cells/µl), and the median CD4\(^+\) nadir cell count was 251 cells/µl (IQR, 160–379 cells/µl).

All study participants received anal cytology examinations. Figure 1 shows the anal cytology findings. Among our study participants, there were 86 (52.8%) normal cytological findings, 25 (15.3%) atypical squamous cells of undetermined significance (ASCUS), 27 (16.6%) low-grade squamous intraepithelial lesion (LSIL), 8 (4.9%) had atypical squamous cells that cannot exclude high-grade squamous intraepithelial lesion (ASCH) and 17 (10.4%) high-grade squamous intraepithelial lesion (HSIL). When compared to HIV seronegatives, HIV seropositives had a higher frequency of abnormal anal cytology results (\(p < 0.001\)). Compared to HIV seronegatives, the prevalence of LSIL (23.8% versus 4.8%, \(p = 0.003\)) and HSIL (15.8% versus 1.6%, \(p = 0.009\)) were significantly higher among HIV seropositives.

Table 2 shows the baseline characteristics among participants with normal or abnormal anal cytology. Participants with abnormal anal cytology tended to be older, seropositive for HIV and had more receptive anal intercourse within one year (\(p < 0.05\)). In addition, participants with abnormal anal cytology showed a prevalence

| Baseline characteristics | Total, n = 163 | HIV-positive MSM n = 101 | HIV-negative MSM n = 62 | \(p\) value |
|--------------------------|---------------|--------------------------|-------------------------|------------|
| Age (years), median (IQR) | 31.0 (27.0–36.0) | 32.0 (28.0–38.0) | 29.0 (26.0–34.0) | 0.004 |
| Cigarette smoking | 31 (19.0) | 26 (25.7) | 5 (8.1) | 0.010 |
| Partnership status | | | | |
| Single/fixed partner | 150 (92.0) | 92 (91.1) | 58 (93.5) | 0.768 |
| Educational status | | | | |
| College or above | 151 (92.6) | 93 (92.1) | 58 (93.5) | 1.000 |
| Income per month | | | | |
| ≥1300 USD | 74 (45.4) | 47 (46.5) | 27 (43.5) | 0.834 |
| Previous HPV vaccination | 19 (11.7) | 10 (9.9) | 9 (14.5) | 0.522 |
| Circumcision | 33 (20.2) | 19 (18.8) | 14 (22.6) | 0.704 |
| No insertive anal intercourse within 1 year | 24 (14.7) | 12 (11.9) | 12 (19.4) | 0.280 |
| No receptive anal intercourse within 1 year | 23 (14.1) | 10 (9.9) | 13 (21.0) | 0.082 |
| Inconsistent condom use | | | | |
| During insertive anal intercourse | 75 (54.0) | 45 (50.6) | 30 (60.0) | 0.371 |
| During receptive anal intercourse | 79 (56.4) | 47 (51.6) | 32 (65.3) | 0.169 |
| >5 sexual partners within 1 year | | | | |
| Insertive anal intercourse | 63 (38.7) | 36 (35.6) | 27 (43.5) | 0.401 |
| Receptive anal intercourse | 50 (30.7) | 28 (27.7) | 22 (35.5) | 0.385 |
| STI within 1 year | 72 (44.2) | 51 (50.5) | 21 (33.9) | 0.056 |
| HIV-related factors | | | | |
| Viral load <40 copies/ml | 79 (78.2) | 47 (46.5) | 32 (65.3) | 0.371 |
| CD4\(^+\) cell count(cells/µl), median (IQR) | 551 (430–730) | 32 (65.3) | 0.169 |
| Nadir CD4\(^+\) cell count(cells/µl), median (IQR) | 251 (160–379) | | |

Table 1. Baseline demographic and clinical characteristics of 163 participants, stratified by HIV status. Human immunodeficiency virus (HIV). Human papillomavirus (HPV). Interquartile range (IQR). Men who have sex with men (MSM). Sexually transmitted disease (STD). United States dollar (USD).
of 23.5% and 17.6% for HPV16 and HPV18 infection, respectively, compared to 5.6% and 2.8% for HPV16 and HPV18 infections among those with normal anal cytology (p < 0.01).

As shown in Table 3, HIV seropositivity and number of detected high-risk HPV showed significant positive associations with anal intraepithelial neoplasia (p < 0.001). On the other hand, the absence of receptive anal intercourse within one year showed negative associations with abnormal anal cytology (p = 0.034). In the multivariate model, only the number of detected high-risk HPV types was significantly associated with abnormal anal cytology, with an adjusted OR of 2.02 (1.27–3.24).

There were 139 (85.3%) participants that had sufficient anal samples for HPV genotyping. Among these men, 81 (58.3%) were HIV seropositive whereas 58 (41.7%) were HIV seronegative. Figure 2 displays the distribution of infection with different HPV types. Among the 37 types of HPV, 66.2% (92/139) of the study participants tested positive for at least one, including 20.9% (29/139) for one HPV type, 13.7% (19/139) for two HPV types, 12.2% (17/139) for three HPV types, 7.2% (10/139) for four HPV types and 12.2% (17/139) for more than four HPV types. Forty-five percent (63/139) had acquired more than one type of anal HPV infection. Multiple HPV infections were more prevalent among HIV seropositive compared to HIV seronegatives (69.1% versus 12.1%, p < 0.001). The overall prevalence of high-risk and low-risk HPV infection was 53.2% (74/139) and 47.5% (66/139), respectively. Compared to HIV seronegatives, HIV seropositives had a significantly higher prevalence of both of high- and low-risk HPV infection types (72.8% versus 25.9%, p < 0.001 for high-risk types and 65.4% versus 22.4%, p < 0.001 for low-risk types). HPV16 (27.0%) and HPV6 (69.7%) were the most common high-risk and low-risk HPV type, respectively. Both were more frequently observed among HIV seropositives than among seronegatives (23.5% versus 1.7%, p < 0.001 for HPV16 and 46.9% versus 13.8%, p < 0.001 for HPV6). We also examined the risk factors associated with high-risk HPV infections (Table 4). In multivariate analyses, HIV seropositivity was the only risk factor associated with low-risk HPV infections (OR 7.00, 95% CI 3.07–15.95).

The prevalence of vaccine-preventable HPV types among the 139 MSM is shown in Table 5. There were 86 (61.9%) and 67 (48.2%) participants that had never acquired any of the HPV types included in the quadrivalent or nonavalent HPV vaccine. Among our study participants, none had acquired all four quadrivalent vaccine HPV types or more than four nonavalent vaccine HPV types. There were significantly fewer detected quadrivalent vaccine types in HIV seronegatives than in seropositives (15.5% versus 54.3%, p < 0.001). The same pattern was seen for nonavalent vaccine HPV types (25.9% versus 70.4%, p < 0.001).

### Discussion

Anal HPV infection is primarily acquired through sexual exposure, especially via anal intercourse. HPV infection contributes substantially to the risk for anal cancer and squamous intraepithelial lesions. However, there is still limited epidemiological studies investigating the association between anal HPV infection and anal intraepithelial lesions among MSM regardless of their HIV infection status, particularly among the Asian population. The study was conducted in a large medical center which provides substantial healthcare for HIV-seropositives as well as pre- or post-exposure prophylaxis for HIV-seronegatives. Because MSM are considered as a high risk group for HIV infection20,21, the participants enrolled in this study should be representative of most of the MSM in northern Taiwan with considerable generalizability. This study showed that both high- and low-risk anal HPV infections were significantly more prevalent in HIV seropositive than in HIV seronegatives. Individuals with increased numbers of acquired HPV types had increased odds of abnormal anal cytology. However, not many individuals (15.5% of HIV seronegatives and 54.3% of HIV seropositives) were infected with at one or more of...
the quadrivalent vaccine types (HPV6, 11, 16, 18), suggesting that the HPV vaccine should be advised in these individuals.

We found that the prevalence of anal HPV infection was 85.2% in HIV seropositives and 39.7% in HIV seronegatives. This HPV prevalence is comparable with other studies conducted in Asian countries. Among MSM seropositive for HIV, the prevalence of HPV infection was 82.7% in China, 85% in Thailand and 85.3% in Taiwan. On the other hand, the prevalence was even higher in Western countries, showing 97% in the United States and 96.3% in Italy. Compared to MSM that were seropositive for HIV, those who were HIV seronegative had consistently lower prevalence of anal HPV infection, which was reported to be 58.5–73.3% and 70% in Asian and Western countries, respectively. Another recent study among MSM of various ethnicities suggested that the estimated global prevalence of anal HPV infection among HIV seropositives and seronegatives was 79% and 47%, respectively.

In terms of HPV types, the most common types of high-risk genital HPV among HIV seropositive MSM in Taiwan were HPV16 (5.9%), HPV51 (7.9%) and HPV52 (7.2%) (20). In Western countries, the most common type was HPV16, with a prevalence of 29.0% (27). However, the prevalence of HPV52 was around 10% (7,27). Our study found the prevalence of HPV16 and HPV52 to be 23.5% and 17.3%, suggesting that anal HPV52 infection among

| Characteristics | Normal cytology n = 86 | Abnormal cytology n = 77 | p value |
|-----------------|------------------------|--------------------------|---------|
| Age, median (IQR), years | 29.5 (26.0–35.0) | 33.0 (28.0–37.0) | 0.015 |
| Positive HIV status | 40 (46.5) | 61 (79.2) | <0.001 |
| Cigarette smoking | 14 (16.3) | 17 (22.1) | 0.458 |
| Partnership status | | | |
| Single/Fixed partner | 80 (93.0) | 70 (90.9) | 0.835 |
| Education status | | | |
| College or above | 82 (95.3) | 69 (89.6) | 0.271 |
| Income | | | |
| ≥1000 USD/month | 36 (41.9) | 38 (49.4) | 0.423 |
| Previous HPV vaccination | 11 (12.8) | 8 (10.4) | 0.816 |
| Circumcision | 18 (20.9) | 15 (19.5) | 0.972 |
| No insertive anal intercourse within 1 year | 12 (14.0) | 12 (15.6) | 0.943 |
| No receptive anal intercourse within 1 year | 17 (19.8) | 6 (7.8) | 0.049 |
| Inconsistent condom use | | | |
| During insertive anal intercourse | 43 (58.1) | 32 (49.2) | 0.380 |
| During receptive anal intercourse | 38 (55.1) | 41 (57.7) | 0.882 |
| >5 sexual partners within 1 year | | | |
| Insertive anal intercourse | 33 (38.4) | 30 (39.0) | 1.000 |
| Receptive anal intercourse | 25 (29.1) | 25 (32.5) | 0.765 |
| STI within 1 year | 34 (39.5) | 38 (49.4) | 0.271 |
| HPV DNA detection | | | |
| Number of detected high-risk HPV genotypes | 0 (0–1) | 1 (0–3) | <0.001 |
| Detection of HPV16 | 4/71 (5.6) | 16/68 (23.5) | 0.006 |
| Detection of HPV18 | 2/71 (2.8) | 12/68 (17.6) | 0.009 |

Table 2. Anal intraepithelial neoplasia among 163 participants. Human immunodeficiency virus (HIV). Human papillomavirus (HPV). Interquartile range (IQR). Sexually transmitted disease (STD). United States dollar (USD).

| Characteristics | Univariate Analysis | Multivariate Analysis |
|-----------------|---------------------|----------------------|
|                | Odds ratio (95% CI) | p value              | Odds ratio (95% CI) | p value              |
| Age            | 1.06 (1.01–1.11)   | 0.022                | 1.05 (0.99–1.13)   | 0.112                |
| Positive HIV status | 4.38 (2.19–8.78)   | <0.001               | 2.04 (0.83–4.98)   | 0.120                |
| No receptive anal intercourse within 1 year | 0.34 (0.13–0.92) | 0.034 | 0.32 (0.08–1.20) | 0.090 |
| HPV DNA detection | | | | |
| Number of detected high-risk HPV genotypes | 2.50 (1.68–3.71) | <0.001 | 2.02 (1.27–3.24) | 0.003 |
| Detection of HPV16 | 5.15 (1.63–16.34) | 0.005 | 1.18 (0.25–5.55) | 0.831 |
| Detection of HPV18 | 7.39 (1.59–34.41) | 0.011 | 1.39 (0.22–8.70) | 0.725 |

Table 3. Factors associated with anal intraepithelial neoplasia among 163 participants. Human immunodeficiency virus (HIV). Human papillomavirus (HPV).
MSM is more prominent and increasing in Taiwan. A majority of anal cancer was attributed to HPV infections\(^6\); nevertheless, the impact of different high-risk HPV types in precancerous lesions on anal cancer has not been clearly identified. The importance of anal HPV52 infection in Taiwan might be worth further investigation.

MSM and increased numbers of acquired high-risk HPV types were found to significantly increase the risk for anal atypical squamous lesions in recent reports\(^{19,21,28,29}\). On the other hand, a meta-analysis suggested that HPV16 infection, but not the number of acquired high-risk HPV types was associated with increased risk for anal cancer\(^7\). This may be due to the fact that the study included different populations, such as HIV seropositive male and female patients regardless of their sexual orientation\(^7\).

In our study, we found that the prevalence of high-risk HPV infection, including HPV16, HPV31, HPV51, HPV56, HPV58 and HPV68, increased with the severity of abnormal anal cytological findings. The prevalence of high-risk HPV was 35.2% for normal anal cytology, 68.9% for LSIL and ASCUS and 78.3% for ASCH and HSIL. These findings are consistent with previous reports\(^{27}\). Interestingly, among those with high-risk HPV infection, the numbers of detected high-risk HPV types also increased with the severity of abnormal anal cytology. The median numbers of detected high-risk HPV infections was 0 (IQR, 0–1) for individuals with normal anal cytology, 1 (IQR, 0–2.5) for ASCUS, 1.5 (IQR, 1–3) for LSIL, and 2 (IQR, 1–3) for ASCH and HSIL. Notably, HIV serostatus was also significantly positively associated with HPV infection. HIV seropositives who are immunosuppressed may be more prone to persistent HPV infection, therefore increasing their risk for anal cancer\(^7,20\). However, given the multitude of HPV types, the impact of multiple HPV infections on anal dysplasia needs further investigation in large-scale studies.

Most anal cancers or precancerous HSIL among MSM are attributed to HPV infection, especially infection via anal intercourse\(^6,18,28,30,31\). Strategies for primary prevention of HPV infection are crucial for the control of anal dysplasia or anal cancer among MSM. Our study found fewer detected quadrivalent or nonavalent vaccine HPV types among HIV seronegatives than among HIV seropositives. Moreover, 61.9% of our study population did not yet acquire any of the HPV types covered in quadrivalent vaccines (HPV6/11/16/18). Thus, this study suggests that there is still a substantial proportion of MSM that may benefit from HPV vaccination. Therefore, increasing

### Table 4. Factors associated with high- or low-risk anal HPV types among 139 participants. Human immunodeficiency virus (HIV). Human papillomavirus (HPV). Interquartile range (IQR). Men who have sex with men (MSM). Sexually transmitted disease (STD).

| Characteristics                                      | Univariate analysis | Multivariate analysis |
|------------------------------------------------------|---------------------|-----------------------|
|                                                      | Odds ratio (95% CI) | p value               |
| High-risk anal HPV infection                         |                     |                       |
| Age, median (IQR), years                            | 1.05 (1.00–1.10)    | 0.072                 |
| Positive HIV status                                 | 7.69 (3.58–16.52)   | <0.001                |
| Cigarette smoking                                   | 3.40 (1.26–9.13)    | 0.015                 |
| Circumcision                                         | 0.34 (0.14–0.86)    | 0.022                 |
| >5 receptive anal sexual partners within 1 year      | 2.09 (0.98–4.46)    | 0.056                 |
| STI within 1 year                                   | 6.34 (2.97–13.53)   | <0.001                |
| Low-risk anal HPV infection                         |                     |                       |
| Age, median (IQR), years                            | 1.01 (0.96–1.06)    | 0.754                 |
| Positive HIV status                                 | 6.55 (3.04–14.13)   | <0.001                |
| Cigarette smoking                                   | 2.28 (0.93–5.58)    | 0.072                 |

Figure 2. Prevalence of various types of anal human papillomavirus infection among men who have sex with men, with and without human immunodeficiency virus infection.
Men who have sex with men (MSM). Human immunodeficiency virus (HIV). Human papillomavirus (HPV). Men who have sex with men (MSM).

Table 5. Prevalence of vaccine-preventable HPV in 139 MSM. Human immunodeficiency virus (HIV). Human papillomavirus (HPV). Men who have sex with men (MSM).

| Number of quadrivalent vaccine HPV types (HPV6/11/16/18) | Total n (%) | HIV-negative n (%) | HIV-positive n (%) | p value |
|--------------------------------------------------------|-------------|--------------------|--------------------|--------|
| 0                                                     | 86 (61.9)   | 49 (84.5)          | 37 (45.7)          | <0.001 |
| 1                                                     | 27 (19.4)   | 8 (13.8)           | 19 (23.5)          | 0.229  |
| 2                                                     | 21 (15.1)   | 1 (1.7)            | 20 (24.7)          | <0.001 |
| 3                                                     | 5 (3.6)     | 0 (0.0)            | 5 (6.2)            | 0.075  |
| 4                                                     | 0 (0.0)     | 0 (0.0)            | 0 (0.0)            | —      |

| Number of nonavalent vaccine HPV types (HPV6/11/16/18/31/33/45/52/58) | Total n (%) | HIV-negative n (%) | HIV-positive n (%) | p value |
|-----------------------------------------------------------------------|-------------|--------------------|--------------------|--------|
| 0                                                     | 67 (48.2)   | 43 (74.1)          | 24 (29.6)          | <0.001 |
| 1                                                     | 32 (23.0)   | 10 (17.2)          | 22 (27.2)          | 0.244  |
| 2                                                     | 23 (16.5)   | 4 (6.9)            | 19 (23.5)          | 0.018  |
| 3                                                     | 10 (7.2)    | 1 (1.7)            | 9 (11.1)           | 0.045  |
| 4                                                     | 7 (5.0)     | 0 (0.0)            | 7 (8.6)            | 0.041  |
| 5                                                     | 0 (0.0)     | 0 (0.0)            | 0 (0.0)            | —      |
| 6                                                     | 0 (0.0)     | 0 (0.0)            | 0 (0.0)            | —      |
| 7                                                     | 0 (0.0)     | 0 (0.0)            | 0 (0.0)            | —      |
| 8                                                     | 0 (0.0)     | 0 (0.0)            | 0 (0.0)            | —      |
| 9                                                     | 0 (0.0)     | 0 (0.0)            | 0 (0.0)            | —      |

In conclusion, we found a high prevalence of anal dysplasia and HPV infection among MSM regardless of their HIV serostatus. Individuals with increased numbers of HPV infections had stronger associations with anal dysplasia. In addition, there were still a substantial number of MSM who had not yet acquired any of the HPV types that are preventable by vaccines. Therefore, MSM should be advised to receive HPV vaccinations.

Methods
Study design and subjects. This cross-sectional study was conducted in a tertiary medical center, Taipei Veterans General Hospital in northern Taiwan. Males at least 20 years of age who reported having regular sex with men in the past 6 months were enrolled from March, 2015 to July, 2016. The MSM who were HIV seropositive were recruited from outpatient clinics during their regular follow-ups. On the other hand, the MSM who were seronegative for HIV were recruited from voluntary HIV testing clinics. These men were confirmed as HIV-negative by Western blot using the recomline HIV-1 & HIV-2 IgG (Mikrogen GmbH, Neuried, Germany) or HIV viral load examination using cobas HIV-1 (Roche Diagnostics, Mannheim, Germany). Participants with a history of sexually transmitted diseases. Clinical data on HIV infection at study entry was obtained by medical chart review with a standardized form. Data on HIV viral load, CD4+ cell count and nadir CD4+ cell count was abstracted.

Data collection. Study subjects were interviewed at study entry using a structured questionnaire (Supplementary questionnaire). The information collected included demographic characteristics (age, educational levels and income), smoking status, partnership (single or fixed partner), sexual behavior within 1 year, HPV vaccination status and his-
first amplified using polymerase chain reaction. Then, the nucleic acid was hybridized to identify 37 anal HPV DNA genotypes, including high-risk types (16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68 and 82) and low-risk types (6, 11, 40, 42, 54, 61, 70, 72, 81 and CP6108)14. The Human β-globin gene was used as a primer for internal control.

**Statistical analysis.** We compared baseline characteristics between HIV seropositive and seronegative MSM and tested differences in categorical variables using Chi-squared or Fisher’s exact tests, while continuous variables using Student-t or Mann-Whitney U tests. We then used logistic regression models to estimate the associations of baseline characteristics (age, HIV seropositivity, receptive anal intercourse, detectable HPV) with intraepithelial neoplasia. In addition, we also investigated possible risk factors associated with high-risk or low-risk HPV types. Odds ratios (ORs) with 95% confidence intervals (CIs) were obtained from the logistic regressions. Two-tailed tests were used to determine statistical significance and a value of p < 0.05 was considered significant. All statistical analyses were performed using SPSS software version 20 (SPSS INC, Chicago, IL, USA).

Received: 14 September 2019; Accepted: 28 January 2020;
Published online: 21 February 2020

**References**

1. Beckmann, A. M. et al. Human papillomavirus infection and anal cancer. *Int. J. cancer* 43, 1042–1049 (1989).
2. Sclafani, F. & Rao, S. Systemic Therapies for Advanced Squamous Cell Anal Cancer. *Curr. Oncol. Rep.* 20, 53, https://doi.org/10.1007/s11912-018-0698-6 (2018).
3. Machalek, D. A. et al. Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: a systematic review and meta-analysis. *Lancet Oncol.* 13, 487–500, https://doi.org/10.1016/S1470-2045(12)70080-3 (2012).
4. Islami, F., Ferlay, J., Lortet-Tieulent, J., Bray, F. & Jemal, A. International trends in anal cancer incidence rates. *Int. J. Epidemiol.* 46, 924–938, https://doi.org/10.1093/ije/dyw276 (2017).
5. Wilkinson, J. R. et al. The rising incidence of anal cancer in England 1990–2010: a population-based study. *Colorectal Dis.* 16, O234–O239, https://doi.org/10.1111/codi.12553 (2014).
6. de Martel, C., Plummer, M., Vignat, J. & Franceschi, S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. *Int. J. Cancer* 141, 664–670, https://doi.org/10.1002/ijc.29716 (2017).
7. Lin, C., Franceschi, S. & Clifford, G. M. Human papillomavirus types from infection to cancer in the anus, according to sex and HIV status: a systematic review and meta-analysis. *Lancet Infect. Dis.* 18, 198–206, https://doi.org/10.1016/S1473-3099(17)30653-9 (2018).
8. Patel, P. et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992–2003. *Ann. Intern. Med.* 148, 728–736 (2008).
9. de Polomandy, A. et al. Prevalence, clearance, and incidence of anal human papillomavirus infection in HIV-infected men: the HPVIRVIG cohort study. *J. Infect. Dis.* 199, 965–973, https://doi.org/10.1086/597207 (2009).
10. Sobhani, I. et al. Anal carcinoma: incidence and effect of cumulative infections. *AIDS* 18, 1561–1569 (2004).
11. Critchlow, C. W. et al. Effect of HIV infection on the natural history of anal human papillomavirus infection. *AIDS* 12, 1177–1184 (1998).
12. Frisch, M. et al. Variants of squamous cell carcinoma of the anal canal and perianal skin and their relation to human papillomaviruses. *Cancer Res.* 59, 753–759 (1999).
13. Daling, J. R. et al. Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. *Cancer* 101, 270–280, https://doi.org/10.1002/cncr.20365 (2004).
14. Sonja, I. K. A. et al. Prevalence of and risk factors for anal high-risk HPV among HIV-negative and HIV-positive MSM and transdermal women in three countries at South-East Asia. *Med. 97*, e9898, https://doi.org/10.1097/MED.0000000000009898 (2018).
15. Nowak, R. G. et al. Prevalence of Anal High-Risk Human Papillomavirus Infections Among HIV-Positive and HIV-Negative Men Who Have Sex With Men in Nigeria. *Sex. Transm. Dis.* 43, 243–248, https://doi.org/10.1097/OLQ.0000000000000431 (2016).
16. Muller, E. E. et al. The prevalence of human papillomavirus infections and associated risk factors in men-who-have-sex-with-men in Cape Town, South Africa. *BMC Infect. Dis.* 16, 440, https://doi.org/10.1186/s12879-016-1706-9 (2016).
17. Phanuphak, N. et al. Anal human papillomavirus infection among Thai men who have sex with men and with HIV infection: prevalence, incidence, and persistence. *J. Acquir. Immune Defic. Syndr.* 63, 472–479, https://doi.org/10.1097/QAI.000000000000183a (2013).
18. de Martel, C. et al. Cancers attributable to infections among adults with HIV in the United States. *AIDS* 29, 2173–2181, https://doi.org/10.1097/QAD.0000000000000808 (2015).
19. Conley, L. et al. Factors associated with prevalent abnormal anal cytology in a large cohort of HIV-infected adults in the United States. *J. Infect. Dis.* 202, 1567–1576, https://doi.org/10.1093/med/56775 (2010).
20. Cheng, S. H., Chu, F. Y., Lin, Y. S. & Hsuie, Y. M. Influence of age and CD4+ T cell counts on the prevalence of genital human papillomavirus infection among HIV-seropositive men who have sex with men in Taiwan. *J. Med. Virol.* 84, 1876–1883, https://doi.org/10.1002/jmv.23413 (2012).
21. Cheng, S. H., Chu, F. Y., Wang, C. C. & Hsuie, Y. M. Screening and risk factors for anal cancer precursors in men infected with HIV in Taiwan. *J. Med. Virol.* 86, 193–201, https://doi.org/10.1002/jmv.23823 (2014).
22. Li, X. et al. Anal HPV/HIV co-infection among Men Who Have Sex with Men: a cross-sectional survey from three cities in China. *Sci. Rep.* 6, 21368, https://doi.org/10.1038/srep21368 (2016).
23. Lin, C. C. et al. Human papillomavirus prevalence and behavioral risk factors among HIV-infected and HIV-uninfected men who have sex with men in Taiwan. *Med. 97*, e13201, https://doi.org/10.1097/MED.00000000000013201 (2018).
24. Niyotray, A. G. et al. Prevalence of and Risk Factors for Anal Human Papillomavirus Infection in a Sample of Young, Predominantly Black Men Who Have Sex With Men, Houston, Texas. *J. Infect. Dis.* 217, 777–784, https://doi.org/10.1093/infdis/jix147 (2018).
25. Ucciferri, C. et al. Prevalence of anal, oral, penile and urethral Human Papillomavirus in HIV infected and HIV uninfected men who have sex with men. *J. Med. Virol.* 90, 358–366, https://doi.org/10.1002/jmv.24381 (2018).
26. Marra, E., Lin, C. & Clifford, G. M. Type-specific anal human papillomavirus prevalence among men, according to sexual preference and HIV status: a systematic literature review and meta-analysis. *J. Infect. Dis.*, https://doi.org/10.1093/infdis/jiy556 (2018).
27. Combes, J. D. et al. Prevalence and Risk Factors for Anal Human Papillomavirus Infection in Human Immunodeficiency Virus-Positive Men Who Have Sex with Men. *J. Infect. Dis.* 217, 1533–1543, https://doi.org/10.1093/infdis/jiy059 (2018).
28. Palefsky, J. M. et al. High incidence of anal high-grade squamous intra-epithelial lesions among HIV-positive and HIV-negative homosexual and bisexual men. *AIDS* 12, 495–503 (1998).
29. Palefsky, J. M. et al. Anal squamous intraepithelial lesions in HIV-positive and HIV-negative homosexual and bisexual men: prevalence and risk factors. *J. Acquir. Immune Defic. Syndr. Hum. Retrovirol.* 17, 320–326 (1998).
30. Silverberg, M. J. et al. Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. Clin. Infect. Dis. 54, 1026–1034, https://doi.org/10.1093/cid/cir1012 (2012).
31. Diamond, C., Taylor, T. H., Aboumrad, T., Bringman, D. & Anton-Culver, H. Increased incidence of squamous cell anal cancer among men with AIDS in the era of highly active antiretroviral therapy. Sex. Transm. Dis. 32, 314–320 (2005).
32. King, E. M. et al. Human papillomavirus DNA in men who have sex with men: type-specific prevalence, risk factors and implications for vaccination strategies. Br. J. Cancer 112, 1585–1593, https://doi.org/10.1038/bjc.2015.90 (2015).
33. Nayar, R. & Wilbur, D. C. The Bethesda system for reporting cervical cytology: definitions, criteria, and explanatory notes. (Springer, 2015).
34. Coutlee, F. et al. Enhanced detection and typing of human papillomavirus (HPV) DNA in anogenital samples with PGMY primers and the Linear array HPV genotyping test. J. Clin. Microbiol. 44, 1998–2006, https://doi.org/10.1128/JCM.00104-06 (2006).

Acknowledgements
This work was supported by the Ministry of Science and Technology (MOST 107-2314-B-075-071) in Taiwan.

Author contributions
M.-H.L., P.-F.W., S.W.-W.K. and J.-F.H. were involved in conceiving this study and data acquisition. M.-H.L. and S.W.-W.K. contributed to experiment design and data interpretation. P.-F.W., C.S., S.-J.C., L.-Y.L, S.-S.C. and C.-R.L. performed the experiments and contributed to data analysis. M.-L.H. and P.-F.W. contributed to manuscript drafting. J.-F.H., C.S. and C.-R.L. contributed to the supervision of this investigation. All of the authors critically revised this manuscript for important intellectual content and approved the final version submitted for publication.

Competing interests
The authors declare no competing interests.

Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41598-020-59967-4.

Correspondence and requests for materials should be addressed to M.-H.L.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2020